St. Cloud Capital Announces Investment In Catawba Research
Summary
It is an investment out of St. Clouds third fund, which has committed capital of $250 million.Catawba is a vertically integrated contract research organization ("CRO") providing clinical management services to pharmaceutical and biotechnology companies globally. The Company focuses on Phase II IV trials across the dermatology, womens health, ophthalmology and gastroenterology therapeutic areas. Since 2014, Catawba Research has engaged in nearly 50 clinical trials in 13 indications, achieving 15 agency approvals in the U.S. and Canada. The Company also provides data management, biostatistics, medical writing and clinical CRO services through its location in Mumbai, India.Zaidoon A. Al-Zubaidy, Chief Executive Officer of Catawba is excited to ally with St. Cloud Capital is a Los Angeles, CA-based private investment firm that provides growth capital to the lower middle market (companies with annual revenues generally between $10 million and $150 million) throughout the United States.